San Diego, CA, United States of America

Amogh Boloor

This inventor holds 33 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Epigenetic Therapeutics. Top assignees: Celgene Quanticel Research, Inc., Glaxosmithkline LLC, Quanticel Pharmaceuticals, Inc.. Active years: 2006-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Amogh Boloor. Retrieved from https://idiyas.com/inventor/amogh-boloor

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 

% Patents Active = 93.9

 

 

Average Co-Inventor Count = 3.0

ph-index = 7

Forward Citations = 194(Granted Patents)


Location History:

  • Lubbock, TX (US) (2006 - 2007)
  • La Jolla, CA (US) (2010 - 2012)
  • San Diego, CA (US) (2015 - 2024)

Company Filing History:


Years Active: 2006-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Histone Demethylase Inhibitors
Bromodomain Inhibitors
Therapeutic Compounds
Chemical Compounds
Pyrimidineamines
Angiogenesis Modulators
Inhibitors
Epigenetics
33 patents (USPTO):Explore Patents

Title: Amogh Boloor: Innovator in Cancer Treatment

Introduction

Amogh Boloor is a prominent inventor based in San Diego, CA, recognized for his significant contributions to the field of cancer treatment through innovative therapeutic compounds. With an impressive portfolio of 33 patents, he has been at the forefront of research aimed at combating various neoplastic diseases.

Latest Patents

Among his latest patents is a groundbreaking invention concerning histone demethylase inhibitors. This invention encompasses compositions and methods designed to treat cancer and neoplastic diseases. The patented substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds, along with their pharmaceutical compositions, provide a new avenue for inhibiting histone demethylase. These compounds are particularly effective for treating various forms of cancer, including prostate cancer, breast cancer, bladder cancer, lung cancer, and melanoma.

Another notable patent involves therapeutic compounds that are substituted heterocyclic derivatives. The embodiments described relate to compositions that facilitate epigenetic regulation via the inhibition of bromodomain-mediated recognition of acetyl lysine regions within proteins, such as histones. These therapeutic methods are invaluable in addressing inflammatory disorders, cancer, and other neoplastic diseases, especially due to their selective activity against CBP compared to BRD4.

Career Highlights

Amogh Boloor has built a noteworthy career working with prominent organizations such as Celgene, Quanticel Research, Inc., and SmithKline Beecham Corporation. His experience in these companies has greatly contributed to his success as an inventor and researcher in oncology.

Collaborations

Throughout his career, Boloor has collaborated with esteemed professionals such as Michael Brennan Wallace and James Marvin Veal. These partnerships have fostered a collaborative environment that has been crucial in advancing his research and innovations.

Conclusion

Amogh Boloor continues to make significant strides in the field of cancer treatment with his innovative inventions and patents. His work not only showcases the importance of research and development in therapeutic solutions but also highlights the impact that dedicated inventors can have on advancing medical science. With a commitment to finding effective treatments for challenging diseases, Boloor is undoubtedly a name to watch in the world of innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…